MTST (MetaStat) Shiller PE Ratio: (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MetaStat Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MetaStat  (OTCPK:MTST) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MetaStat Shiller PE Ratio Related Terms


MetaStat Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for MetaStat's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Shiller PE Ratio Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MTST vs OBMP, NSPX, ATRX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, MetaStat's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MetaStat's Shiller PE Ratio falls into.



MetaStat Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MetaStat's E10 for the quarter that ended in Feb. 2018 is calculated as:

For example, MetaStat's adjusted earnings per share data for the three months ended in Feb. 2018 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Feb. 2018 (Change)*Current CPI (Feb. 2018)
=-0.17/248.9910*248.9910
=-0.170

Current CPI (Feb. 2018) = 248.9910.

MetaStat Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200805 -2.100 216.632 -2.414
200808 -4.500 219.086 -5.114
200811 -4.500 212.425 -5.275
200902 -1.500 212.193 -1.760
200905 0.000 213.856 0.000
200908 0.000 215.834 0.000
200911 0.000 216.330 0.000
201002 -1.350 216.741 -1.551
201005 -1.050 218.178 -1.198
201008 -0.600 218.312 -0.684
201011 -0.600 218.803 -0.683
201102 -8.879 221.309 -9.990
201105 0.450 225.964 0.496
201108 -0.150 226.545 -0.165
201111 -0.300 226.230 -0.330
201202 -0.750 227.663 -0.820
201205 -0.300 229.815 -0.325
201208 -0.600 230.379 -0.648
201211 -0.450 230.221 -0.487
201302 -0.450 232.166 -0.483
201305 -1.200 232.945 -1.283
201308 -0.750 233.877 -0.798
201311 -0.750 233.069 -0.801
201402 -1.200 234.781 -1.273
201405 -0.900 237.900 -0.942
201408 -2.505 237.852 -2.622
201411 -0.790 236.151 -0.833
201502 -0.660 234.722 -0.700
201505 -1.210 237.805 -1.267
201508 -0.730 238.316 -0.763
201511 -0.720 237.336 -0.755
201602 -0.630 237.111 -0.662
201605 -1.080 240.229 -1.119
201608 -0.460 240.849 -0.476
201611 -1.160 241.353 -1.197
201702 0.109 243.603 0.111
201705 -0.060 244.733 -0.061
201708 -0.160 245.519 -0.162
201711 -0.210 246.669 -0.212
201802 -0.170 248.991 -0.170

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.